Sex differences in patient-reported outcomes and the association with clinical factors in axial spondyloarthritis patients treated with tumour necrosis factor inhibitors.

Autor: Hellamand P; Department of Clinical Immunology and Rheumatology, Amsterdam UMC, location AMC, Free University of Amsterdam, Netherlands, Amsterdam.; Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands., van de Sande MGH; Department of Clinical Immunology and Rheumatology, UMC, location AMC, University of Amsterdam, Netherlands, Amsterdam, Amsterdam.; Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands., Nurmohamed MT; Amsterdam Rheumatology and Immunology Center (ARC), Reade and Amsterdam UMC, Amsterdam, Netherlands., van Vollenhoven RF; Department of Clinical Immunology and Rheumatology, Amsterdam UMC, location AMC, Netherlands, Amsterdam.; Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands., Hollick RJ; Aberdeen Centre for Arthritis and Musculoskeletal Health (Epidemiology Group), University of Aberdeen, Aberdeen, United Kingdom., Rotariu O; Aberdeen Centre for Arthritis and Musculoskeletal Health (Epidemiology Group), University of Aberdeen, Aberdeen, United Kingdom., Rotar Z; Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia.; Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia., Pirkmajer KP; Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia.; Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia., Nordström D; Departments of Medicine and Rheumatology, Helsinki University Hospital, Helsinki, Finland., Hokkanen AM; Department of Medicine, Helsinki University and Helsinki University Hospital, Helsinki, Finland., Michelsen B; Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway.; Research Unit, Sørlandet Hospital, Kristiansand, Norway.; Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark., Kvien TK; Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway., Glintborg B; DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark., Hetland ML; DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark., Østergaard M; Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark., Loft AG; DANBIO and Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark.; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark., Pavelka K; Institute of Rheumatology, Prague, Czech Republic.; Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic., Zavada J; Institute of Rheumatology, Prague, Czech Republic.; Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic., Castrejon I; Department of Rheumatology, Hospital General, Universitario Gregorio Marañón, Madrid, Spain.; Faculty of Medicine, Complutense University of Madrid, Madrid, Spain., Otero-Varela L; Research Unit, Spanish Society of Rheumatology, Madrid, Spain., Gudbjornsson B; Centre for Rheumatology Research, Landspitali University Hospital, Reykjavik, Iceland.; Faculty of Medicine, University of Iceland, Reykjavik, Iceland., Palsson O; Faculty of Medicine, University of Iceland, Reykjavik, Iceland.; Department of Clinical Sciences Lund, Rheumatology, Skåne University Hospital, Lund University, Lund, Sweden., Olofsson T; Department of Clinical Sciences Lund, Rheumatology, Skåne University Hospital, Lund University, Lund, Sweden., Wallman JK; Department of Clinical Sciences Lund, Rheumatology, Skåne University Hospital, Lund University, Lund, Sweden., Ciurea A; Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland., Nissen MJ; Department of Rheumatology, Geneva University Hospital, Geneva, Switzerland., Yildirim TD; Division of Rheumatology, Department of Internal Medicine, Dokuz Eylul University School of Medicine, Izmir, Turkey., Onen F; Division of Rheumatology, Department of Internal Medicine, Dokuz Eylul University School of Medicine, Izmir, Turkey., Codreanu C; Center for Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania., Mogosan C; Center for Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania., Santos MJ; Reuma.pt and Department of Rheumatology, Hospital Garcia de Orta, Almada, Portugal.; Instituto Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Centro Académico de Medicina de Lisboa, Lisbon, Portugal., Vieira-Sousa E; Reuma.pt and Department of Rheumatology, Hospital Garcia de Orta, Almada, Portugal.; Instituto Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Centro Académico de Medicina de Lisboa, Lisbon, Portugal., Iannone F; Rheumatology Unit, DiMePRe-J, University of Bari, Bari, Italy., Frediani B; Department of Medicine, Surgery and Neurosciences, Rheumatology Unit, University of Siena, Siena, Italy., Ørnbjerg LM; Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark., Twisk JWR; Department of Epidemiology and Data Science, Amsterdam UMC, Amsterdam, Netherlands., van der Horst-Bruinsma IE; Department of Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands.
Jazyk: angličtina
Zdroj: Rheumatology (Oxford, England) [Rheumatology (Oxford)] 2024 Jul 23. Date of Electronic Publication: 2024 Jul 23.
DOI: 10.1093/rheumatology/keae370
Abstrakt: Objectives: To investigate sex differences in patient-reported outcome measures (PROMs) among axSpA patients initiating their first TNFi and identify factors contributing to these disparities over the follow-up.
Methods: Data were included from 15 EuroSpA registries and consisted of axSpA patients initiating their first TNFi, with ≥2 measurements for each analysed PROM (BASDAI and BASFI, scale 0-100) taken at any time point. Linear mixed models were employed to analyse sex differences in PROMs over 24 months and to evaluate how baseline characteristics were related to the observed sex differences.
Results: We analysed 13 102 (38% women) in the BASDAI analyses and 10 623 (38% women) in the BASFI analyses. At follow-up, mean sex differences in BASDAI increased from 4.3 units at baseline (95% CI, 3.5-5.1)-8.0 (7.2-8.8) at 6 months, and in BASFI from 2.2 (1.4-3.1)-4.6 (3.6-5.5), with consistently worse scores in women. Baseline characteristics could not substantially account for the observed sex differences over time; however, the magnitude of the sex differences was reduced by HLA-B27 positivity, longer disease duration, and increased CRP levels, but increased by TNFi initiation in later years and peripheral arthritis.
Conclusion: In axSpA patients initiating their first TNFi, baseline sex differences in BASDAI and BASFI increased two-fold after 6 months of treatment and persisted thereafter, with worse scores in women. Several baseline characteristics moderated the sex differences, though none could fully account for them. These findings improve our understanding of sex differences and underscore their importance in axSpA.
(© The Author(s) 2024. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
Databáze: MEDLINE